GLP-1 Receptor Agonist Therapy in Adults With Sickle Cell Disease and Type 2 Diabetes: A Real-World Cohort Analysis
Nguefang GL, Boateng S, Gyabaah S, Issaka Y, Konlack JG, Landa EL, Eze E, Njei B
Summary
This real-world study of 1,391 matched patients with sickle cell disease (SCD) and type 2 diabetes found that GLP-1 receptor agonist therapy was associated with a 39% reduction in major adverse cardiovascular events (HR 0.61), 53% reduction in stroke risk (HR 0.47), and 36% reduction in vaso-occlusive crises (HR 0.64) over 12 months. There was no increased risk of hypoglycemia compared to controls.
Clinical Significance
First large-scale evidence supporting GLP-1 RA use in the high-risk SCD+T2DM population, demonstrating cardiovascular and vaso-stabilizing benefits beyond glycemic control. This opens a new therapeutic window for peptide therapy in hematological disorders where treatment options are limited.
Sorodne raziskave
Determinants of VO2peak Responsiveness to Aerobic Exercise Training in Adults with Type 2 Diabetes: The PROTECTION Study
In 108 adults with Type 2 diabetes participating in a 26-week supervised cycling programme, GLP-1 re…
Association of Dual SGLT-2 Inhibitor and GLP-1 Receptor Agonist Therapy with Colon Cancer Risk in Post-Polypectomy Patients with Diabetes: A Target Trial Emulation
This target trial emulation study examined whether dual SGLT-2 inhibitor and GLP-1 receptor agonist …
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…